



International Federation of Associations  
of Pharmaceutical Physicians &  
Pharmaceutical Medicine

---

## IFAPP TODAY - NUMBER 2, MAY 2020

---

Dear Colleagues,

It is with great pleasure that we would like to welcome all the new members to our IFAPP Communication Working Group (WG), who bring us closer to our goal of true global representation.

The Communication WG members are now, (in alphabetical order) :

Raeefuddin Ahmed (Pakistan), Varvara Baroutsou (Greece), Frank Bringstrup (Sweden), Domenico Criscuolo (Italy), Brigitte Franke-Bray (Switzerland), Epainète Gawa (France), Qaddafi Jahangir (Pakistan), Ji-Hyun Kim (Korea), Rob van Maanen (the Netherlands), Hasan Mahmood (Bangladesh), Koto Matsuyama (Japan), Anna Rodet (France), Ajay Tiku (Singapore), Johanna Schenk (Germany), Peter Stilting (the Netherlands) and Chinnie Tan (Philippines).

In each forthcoming issue of IFAPP TODAY, we will introduce a new member, starting with Ji-Hyun Kim from the Korean Society of Pharmaceutical Medicine (KSPM).

### Introduction Ji-Hyun Kim



**Name:** Ji-Hyun Kim, MD, PhD

**Medical specialty:** Board-certified psychiatrist

**Current position:** Cardiovascular Medical Lead, Medical Affairs, Sanofi Korea (since 2018)

**Current Korean Society of Pharmaceutical Medicine (KSPM) position:** Public Relations Director

**Company e-mail address:** [ji-hyun.kim@sanofi.com](mailto:ji-hyun.kim@sanofi.com)

**KSPM e-mail address:** [relations@kspm.org](mailto:relations@kspm.org) (not activated yet)

**Introductory comment:**

Dear IFAPP members,

My name is Ji-Hyun Kim, MD, PhD. I am pleased to join IFAPP as a Communication Working Group member and hope the great partnership continues between KSPM and IFAPP. I am a board-certified psychiatrist who worked in teaching hospitals until my first joining the industry in January 2018. Since then I have been working for Sanofi Korea as the cardiovascular medical lead. I decided to move to the pharma industry hoping to contribute to a greater good in this age of healthcare innovation. In recent years, we have been witnessing drastic changes in which novel bio-products are saving lives and the healthcare system is rapidly transforming into something unprecedented. Although I still love being a psychiatrist, now I find excitement and joy in discovering the process of developing not only “products” but also “knowledge”. I hope joining IFAPP helps me to see the bigger picture from a global perspective and to contribute to strengthening the multinational partnership in Pharmaceutical Medicine. Thank you very much for this opportunity.

**Education and Training Background:**

2002 Seoul National University College of Medicine, MD

Mar. 2002 - Feb. 2003: Medical Intern, Seoul National University Hospital

Mar. 2003 - Feb. 2007: Resident, Department of Neuropsychiatry, Seoul National University Hospital

**Professional Experience:**

May 2010 - Apr. 2011: Clinical fellow, Department of Neuropsychiatry, Seoul National University Hosp.

May 2011 - Feb. 2012: Research assistant professor, Seoul National University Hospital Biomed Inst.

Mar. 2012 - Aug. 2012: Clinical instructor, Department of Psychiatry, Daegu Catholic University Med.

Sep. 2012 - Feb. 2015: Assistant professor, Department of Psychiatry, Catholic University of Daegu

Mar. 2015 - Dec. 2017: Clinical assistant professor, Department of Psychiatry, Inha University Hospital

Jan. 2018 - Present: Cardiovascular Medical Lead, Medical Affairs, Sanofi Korea

## COVID-19 R&D: An Important Area of International Collaboration



The COVID-19 pandemic has changed our working styles and habits, but an interesting and positive consequence is the global collaboration to fight this new disease. Please find below an interesting summary of several ongoing activities in the area of clinical trials prepared by our WG member Varvara Baroutsou, President of EL.E.F.I., the Greek Society of Pharmaceutical Medicine ([www.elefi.gr](http://www.elefi.gr)).

**COVID-19 R&D: An Important Area of International Collaboration.**

Health care systems and Health Care Professionals are in a warpath to curb the coronavirus pandemic

without proven pharmacological treatments and no available vaccine to prevent SARS-CoV-2 infection. Due to the high risk public health emergency, several repurposed drugs and investigational agents are being studied in clinical trials for their safety and efficacy as treatments and or pre-exposure or post-exposure prophylactic strategies as registered in [WHO ICTRP](#). In parallel, a rich [COVID-19 vaccine pipeline](#) of novel DNA, mRNA & other candidates are mainly in preclinical research or in early clinical development – Phase I, with a vaccine becoming available still 12-18 months away.

An unprecedented spirit of international collaboration has led to important coalitions pursuing acceleration of COVID-19 R&D to control SARS-CoV-2 infection under [WHO](#) coordination.

Namely the newly founded [COVID-19 Clinical Research Coalition](#) will synergize with existing initiatives, such as the [COVID-19 Therapeutics Accelerator](#), the [Coalition for Epidemic Preparedness Innovations \(CEPI\)](#), and the [SARS-CoV-2 Diagnostic Pipeline](#), to ensure research interventions are well designed, properly sized and adequately powered to generate robust evidence, to tackle COVID -19 infection. A special mention is due to the [Solidarity](#) Trial, an international adaptive controlled trial comparing four treatments, launched by WHO and its partners, which is expected to deliver evidence in the coming 12-16 weeks.

Moreover a close collaboration on COVID-19 observational research and real world data between international medicines regulators was announced post a [virtual global regulatory workshop](#) organized by the umbrella coalition [ICMRA](#) and co -chaired by Health Canada and EMA. ICMRA brings medicine regulators worldwide to exchange information, build synergies for expediting COVID-19 medicines, vaccine development and approval. During these challenging times, the research community ecosystem has exercised vigorous Open Science, Transparency and Data Sharing practices for combatting the SARS-CoV-2 pandemic.

Varvara Baroutsou, MD, PhD, Internist, EMAUD, GFMD

President of Greek Society of Pharmaceutical Medicine

EL.E.F.I.- [www.elefi.gr](http://www.elefi.gr)

April 26, 2020

### New IFAPP ‘Company Page’ on LinkedIn – Are You Already a ‘Follower’?



Prof. Brigitte Franke-Bray, IFAPP Treasurer, Prof. Peter Stonier, Director of Education & Training, FPM, Ana Rodet, Responsable Medical, Zambon France, Dr. Marco Romano, IFAPP President-Elect, Dr. Anna Jurczynska, Junta Directiva de AMIFE, Prof. Kyoko Imamura, IFAPP President (from left)

Less than three weeks after its launch, the number of followers exceeded the ‘magic’ number of 100. With this new communication platform IFAPP intends to reach out to more than the currently 569 pharmaceutical medicine professionals with member status in the traditional IFAPP ‘group page’ on

LinkedIn. Please consider becoming a 'follower' of the IFAPP company page. From there you can share posts with your own comments and deliberations. You will find the new platform when you 'Search' on LinkedIn for 'Companies', and then enter 'IFAPP'.

---

---



---

*Copyright © \*2020\* \*IFAPP\*, All rights reserved.*

**Our e-mail address is:**

[\\*secretariat@ifapp.org\\*](mailto:*secretariat@ifapp.org)

You will find our informative website at [www.ifapp.org](http://www.ifapp.org).

---